FDA approves Zinbryta to treat multiple sclerosis

The US Food and Drug Administration on Friday approved Zinbryta (daclizumab) for the treatment of adults with relapsing forms of multiple sclerosis (MS).

Zinbryta is a long-acting injection that is self- administered by the patient monthly developed by US companies Biogen (Nasdaq: BIIB) and AbbVie (NYSE ABBV).

Zinbryta should generally be used only in patients who have had an inadequate response to two or more MS drugs because Zinbryta has serious safety risks, including liver injury and immune conditions. Because of the risks, Zinbryta has a boxed warning and is available only through a restricted distribution program under a Risk Evaluation and Mitigation Strategy, the FDA stated.